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Abstract
Spastic paraplegia gene 11(SPG11)-linked hereditary spastic paraplegia is a complex monogenic neurodegenerative disease
that in addition to spastic paraplegia is characterized by childhood onset cognitive impairment, thin corpus callosum and
enlarged ventricles. We have previously shown impaired proliferation of SPG11 neural progenitor cells (NPCs). For the
delineation of potential defect in SPG11 brain development we employ 2D culture systems and 3D human brain organoids
derived from SPG11 patients’ iPSC and controls. We reveal that an increased rate of asymmetric divisions of NPCs leads to
proliferation defect, causing premature neurogenesis. Correspondingly, SPG11 organoids appeared smaller than controls
and had larger ventricles as well as thinner germinal wall. Premature neurogenesis and organoid size were rescued by GSK3
inhibititors including the Food and Drug Administration-approved tideglusib. These findings shed light on the
neurodevelopmental mechanisms underlying disease pathology.
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Introduction
Mutations in ALS5/SPG11/KIAA1840-encoding SPATACSIN cause
a spectrum of neurodevelopmental and neurodegenerative dis-
eases including the most frequent form of autosomal recessive
hereditary spastic paraplegia (HSP) (36), termed spastic paraple-
gia gene 11 (SPG11), young onset amyotrophic lateral sclerosis
(ALS5) (28) and Charcot–Marie–Tooth disease (CMT1a) (26).
Spatacsinopathies converge a clinical spectrum ranging from
cognitive impairment and thin corpus callosum (TCC) to spastic
paraplegia and peripheralmotor neuropathy.Thismultisystemic
involvement points towards distinct temporal and spatial, yet
incompletely understood functions of SPATACSIN. The promi-
nent nervous system involvement in SPG11-linked HSP is con-
nected to SPATACSIN’s active temporal and spatial expression
throughout the nervous system. The neurodegenerative pheno-
typewas linked to autophagy: togetherwith another HSP-related
protein (ZFYVE26), the SPG11 protein SPATACSIN is instru-
mental for the reformation of lysosomes from autophagolyso-
somes, i.e. a recycling pathway that generates new lysosomes
(7,39).
Among others, SPG11-HSP belongs to a subset of complex
forms of HSPs characterized by TCC and is often associated with
cognitive impairment (15), indicative of a neurodevelopmental
defect. In conjunction, amajority of SPG11 patients showmild to
severe enlargement of the lateral ventricles and of the cerebral
sulci, in addition to a TCC and diffuse white matter hyperinten-
sity (31).
The functional role of SPG11 in neurodevelopmental alter-
ations remains largely unexplored. Induced pluripotent stemcell
(iPSC)-derived neuronal models have been decisive for charac-
terizing the cellular phenotypes of neurodevelopmental deficits
in autism, Rett syndrome and Williams syndrome (6,22,23).
We have previously described a proliferation deficit in neural
progenitor cells (NPCs) derived from SPG11 patients’ iPSC (25).
More recently, 3D iPSC-derived organoid systems opened the
opportunity tomodel brain diseases in a systemwith remarkable
similarities to human organogenesis (18,24,34).
Here, we took advantage of the cerebral organoid system
and of live-cell imaging to recapitulate the temporal and
spatial pattern of NPC division and differentiation in SPG11-
HSP patients. Using 2D and 3D culture conditions, namely
differentiating NPCs, neurospheres and cerebral organoids, we
identified an increased asymmetric division in SPG11-NPCs
at the germinal zone of cortical ventricles at the expense of
symmetric division.This impairment in self-renewal contributes
to the premature generation of cortical neuroblasts and
neurons and is dependent on GSK3 signaling. Inhibition of
GSK3 activity using the Food and Drug Administration (FDA)-
approved compound tideglusib is sufficient to rescue premature
neurogenesis and more importantly increases organoid size
in SPG11. Our data provide insights into how SPG11 alters
neurodevelopment and further links this disease to the group of
neurodevelopmental disorders. Moreover, we provide a proof of
concept that 3D brain organoids are valuable tools for precision
medicine.
Results
SPG11 patients and controls included in the study
The SPG11-HSP patients reported in this study are characterized
by an early onset of cognitive impairment in the first and
second decade (15). In total, we derived iPSC from three
patients (two lines each), referred to as SPG11-1, SPG11-2 and
SPG11-3. SPG11-1 and SPG11-2 are sisters with compound
heterozygous mutations c.3036C>A/ p.Tyr1012X in exon 16
and c.5798 delC/ p.Ala1933ValfsX18 in exon 30. SPG11-3 has
compound heterozygous mutations at c.267G>A/ p.Trp89X in
exon 2 and at 1457-2A>G in intron 6 (splice site mutation
corresponding to the previously reportedmutation c.1757-2A>G)
(15). The detailed clinical, genetic and imaging characteristics of
the patients were previously published (15). The controls are two
age-matched healthy Caucasian individuals with no history of
movement disorder or neurologic disease.
SPG11-NPCs display an altered self-renewal pattern
in cerebral organoids
To experimentally mimic the temporal and spatial division
of neural cells in SPG11 patients and controls, we generated
and analyzed cerebral organoids derived from iPSC. The
size of organoids derived from SPG11-iPSC (SPG11 organoids)
was significantly smaller compared to controls during early
development of the organoids (6 days) andwas not compensated
over time (6 weeks, Fig. 1A and B). Organoids developed a
structural organization into germinal zones and cortical regions
(Fig. 1C; Supplementary Material, Fig. S1A). Germinal zones of
SPG11 organoids cultured for both 6 and 9 weeks contained
significantly less proliferating phospho-histone H3 positive
(PH3+) cells when compared to controls (Fig. 1D, E and G). The
thickness of the progenitor zone was significantly reduced in
SPG11 organoids after 9 weeks, but not at 6 weeks (Fig. 1F and H),
indicating that fewer dividing cells impact the thickness of the
germinal wall already at 6 weeks (young organoid stage). In
addition, the lumen of the ventricles appeared larger in SPG11
organoids compared to controls (Fig. 1D). It is important to
note that cell death levels did not differ between controls and
SPG11 organoids (Supplementary Material, Fig. S5), possibly due
to a constant rate of ongoing cell death occurring in cerebral
organoids model (21).
While vertically dividing NPCs in the apical ventricular zone
result in two daughter cells (symmetric division), horizontal
(asymmetric) divisions give rise to one stem cell and one neu-
roblast (13,27). Spindle orientations were evaluated by analyzing
division angles of nuclear mitotic apparatus-positive cells in the
progenitor zone of organoids.We found a significantly increased
amount of horizontally dividing cells at the expense of vertically
dividing cells in SPG11 organoids, indicating a shift towards
asymmetric division in SPG11 (Fig. 1I and J). We also noticed
structural changes in the ventricular zone; while the apico-basal
polarity was correctly established as shown by ß-catenin (ßCat)
staining next to the ventricle-like lumen, the progenitor zone
and the cortical plate were less clearly separated as visible by
more neuroblasts within the progenitor zone in SPG11 organoids
(Fig. 1D; Supplementary Material, Fig. S1B and C).
Longer cell cycle duration in SPG11-NPCs
To explore the duration and the frequency of cell division, we
carried out single-cell tracking time-lapse microscopy in SPG11-
and control-NPCs (Supplementary Material, Fig. S1D). SPG11-
NPCs underwent lesser divisions than controls after 6 days
in culture (Supplementary Material, Fig. S1E). To follow the
fate of individual cells and their progeny, single-cell tracking
of GFP-labeled NPCs was performed acquiring phase contrast
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Figure 1. Altered size and self-renewal pattern in SPG11 organoids. (A) Representative bright field images of 6-day-old cerebral organoids generated from SPG11- and
control-iPSCs. (B) Significant decrease in total organoid size in SPG11 at 6 weeks (∗∗∗∗P < 0.0001; n ≥ 9 organoids per group). (C) Control cerebral organoids with apical
progenitor zones (Sox2+, green) and basal neurons (Map2+ , red). (D) Cerebral organoids from control- and SPG11-iPSCs, cultured for 9 weeks. PH3 (green): proliferating
cells, nestin (red): NPCs, DCX (grey): neuroblasts. Apical surface indicated by dotted lines. Quantification of (E–H) PH3+-cells in the progenitor zone per 100 μm apical
surface length, progenitor zone thickness (μm) of 6-week-old (E, F) and 9-week-old (F, H) organoids, respectively (∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001, ∗∗∗∗P < 0.0001;
n ≥ 5 organoids per group). (I) Orientation of NuMA+ cells (green): horizontal and vertical divisions (micrographs exemplify angle of division). Nuclei labeled with DAPI
(red). (J) Percentage of NuMA+ cells undergoing horizontal and vertical division at the ventricle wall of 6-week-old organoids (∗∗∗∗P < 0.0001; n ≥ 200 cells per group).
Controls were grouped in (B), E–J). All data: mean ± SD. Scale bars: 200 μm in (A), (C), (D). 5 μm in (I).
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Figure 2. SPG11-NPCs undergo premature neurogenesis. (A) NPC spheres from controls and SPG11 patients; NPCs (green) and neuroblasts (red) were labeled with anti-
Sox2 and anti-DCX, respectively. (B, C) Quantification of migrating DCX+- and Sox2+-cells in relation to the area of the assessed spheres (dotted lines: borders of the
analyzed area; ∗∗∗∗ P < 0.0001 for all comparisons of control versus SPG11-1, SPG11-2, and SPG11-3; n ≥ 24 spheres per group). (D) Neuronal differentiation of NPCs,
labeled for the neuronal marker ßIIITubulin (ßIIITub; green), the astrocyte marker GFAP (red), and DAPI (blue). (E–G) The numbers of ßIIITub+-cells are significantly
decreased in SPG11 patients’ lines at 2, 4 and 8 weeks of differentiation when compared to control (∗P < 0.05, ∗∗∗P < 0.001, ∗∗∗∗P < 0.0001; n ≥ 10 per group). (H)Neuronal
differentiation of NPCs, labeled for ßIIITub (green) and the cell death dye IT-DEAD (magenta), DAPI (blue). Arrows indicate dead neurons. (I–K) Significantly increased
numbers of dead cells in SPG11 cortical cultures at 2 (I), 4 (J) and 8 (K) weeks in culture (∗∗∗∗P < 0.0001 for all comparisons of control versus SPG11-1, SPG11-2, and
SPG11-3; n ≥ 26 per group). All data: mean ± SD. Scale bars: 200 μm [overview (A)] and 50 μm [magnification (A), (D) and (H)].
and fluorescent images every 8 and 160 min, respectively.
The temporal analysis showed significantly reduced division
rounds per clone in SPG11-NPCs (Supplementary Material,
Fig. S1F and G) and delineated that SPG11-NPCs need more
time to complete a full-cell cycle (Supplementary Material,
Fig. S1H).
Premature neurogenesis in SPG11-NPCs
To evaluate changes inmigration and neuronal differentiation in
NPCs,we analyzed neural stem cell (Sox2/Nestin) and neuroblast
markers (DCX) in NPCs growing in spherical structures under
mitogenic culture conditions as neurospheres (3). When
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Figure 3. GSK3 overactivation in SPG11. (A–E) HEK cells transfected with control siRNA (siLuc) and siRNA against spatacsin (siSPG11). β-Actin served as loading control.
(A) Demonstration of spatacsin knockdown in HEK cells upon siSPG11 transfection, but not siLuc transfection. (B) Western blots of hyperphosphorylated βCat (P-βCat),
total βCat, inactivated (PS9-βGSK3) and total βGSK3. (C) Quantification of P-βCat. Data were related to total βCat (∗∗∗P < 0.001; n = 3). (D) Quantification of PS9-βGSK3,
related to total βGSK3 (no significant change; n = 3). (E) Western blots of protein preparations of untreated control- and SPG11-organoids, blotted for the same proteins
as in (B). (F) Quantification of P-βCat in control- and SPG11-organoids. Data were related to total βCat (∗∗P < 0.01; n = 3). (G) PS9-βGSK3 in control- and SPG11-organoids.
Data were related to total βGSK3 (∗∗P < 0.01; n = 3). All data: mean ± SD.
quantifying cells migrating out from the sphere borders 48 h
after plating, significantly more DCX+-cells were present in
the SPG11 groups, indicating an increased number of migrat-
ing neuroblasts (Fig. 2A and B). As expected, the number of
Sox2-positive NPCs was significantly reduced in SPG11, while no
GFAP-positive cells were present (Fig. 2A and C; Supplementary
Material, Fig. S2A). This indicates an increase of migrating
neuroblasts at the expense of NPCs, which is in line with the
shift in division towards an asymmetric pattern in organoids.
To test if premature neurogenesis, associated with the dys-
function of SPG11, implies a decrease in the total number of
neurons, we induced neuronal differentiation in SPG11-NPCs.
Compared to controls, SPG11-NPCs differentiated for 2, 4 and
8 weeks showed a severe reduction of neurons (Fig. 2D–G) and
significantly increased rates of cell death (Fig. 2H–K). The num-
ber of GFAP-positive astrocytes was unchanged in weeks 2 and
4. There was a significant increase in GFAP-positive astrocytes at
week 8 (Supplementary Material, Fig. S2B).
Partners for the modulation of neurogenesis
in spatacsinopathies
SiRNA-mediated knockdown of SPG11 was performed to model
SPATACSIN loss of function in HEK cells (Fig. 3A). P-ßCat lev-
els were significantly increased upon SPG11-siRNA transfec-
tion when compared to control luciferase-siRNA transfection
(Fig. 3B and C). βGSK3 activity is regulated by phosphorylation
at specific sites and phosphorylation of serine-9 (PS9-βGSK3)
results in inactivation (16). In SPG11-silenced cells, despite a
trend, the inactivated form of βGSK3 (PS9-βGSK3) was unaltered
(Fig. 3D).
Since this result might have been influenced by the cell type
(HEK cells) used for the analysis and to proceed towards the
crucial step of translating these findings into precisionmedicine,
knowledge about the biochemical changes in complex neu-
ral models is essential. We thus analyzed components of the
GSK3/βCat pathway in SPG11 organoids. Dysregulation of βGSK3
was also observed in SPG11 organoids, i.e. P-ßCat levels were
increased and PS9-βGSK3 levels were significantly decreased
(Fig. 3E–G).
Phosphorylated cAMP response element-binding protein
(pCREB) is a key factor in the regulation of neurogenesis (12) and
previous studies described a direct interaction between pCREB
and three amino acids in βGSK3 (17). We therefore investigated,
if activated CREB (Supplementary Material, Fig. S3A and B)
is altered in SPG11-NPCs. We found a significant increase in
SPG11-NPCs, indicative of increased transcription of neurogenic
genes (20). These findings imply that premature activation of
neurogenesis in SPG11 was driven by a concomitant repression
of proliferative pathways of the Wnt/ßCat system.
Modulation of the GSK3/β-catenin pathway rescues
SPG11 phenotypes
In a first step, we investigated how the premature neurogenesis
phenotype in SPG11 can be rescued.We first tested in SPG11- and
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Figure 4. Rescue of premature neurogenesis in SPG11-NPCs. (A) Images of untreated (left) and tide-treated (right) control- and SPG11-NPCs. The cells were stained
for EdU (orange), Ki-67 (green) and DCX (purple). Proliferating cells are indicated with arrows. (B) Quantification of the percentage of Ki-67-positive cells out of
DCX-positive cells, with representation of the subpopulation of EdU/Ki-67/DCX-positive cells within the proliferative population of neuroblasts (DCX+). (C) Images
of SPG11-NPCs, untreated (NT) or treated with tideglusib (Tide) and stained for DCX (red). (D) Quantification of the percentage of neuroblasts (DCX+) in relation to
the total number of cells. Three control NPC lines (grouped) and SPG11-NPC lines (SPG11-1 and SPG11-2, SPG11-3, respectively) were analyzed (n ≥ 20 per condition).
(E) Non-treated (NT) and CHIR-treated neurospheres generated from SPG11-NPCs, labeled with DCX (red) and Sox2 (green). (F) Quantification of DCX+-cells in NT or
CHIR-treated spheres per mm2 (n ≥ 20 per condition). ∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001; ∗∗∗∗P < 0.0001. Data in (D), (F): mean ± SD; data in (B): mean ± SEM. Scale
bars: 50 μm.
control-NPCs whether overexpression of SPATACSIN was able to
rescue premature neurogenesis. Overexpression of SPATACSIN
reduced the number of DCX+-cells in SPG11-NPCs under
proliferating conditions (Supplementary Material, Fig. S3C–E),
indicating that restoration of SPATACSIN levels can revert the
phenotype. To further examine proliferation of SPG11 neurob-
lasts,we labeled NPCs with EdU 1 h before harvesting (paradigm:
Supplementary Material, Fig. S4B). We then counted EdU/KI67/
DCX-positive cells within the total population of KI67/DCX
double positive cells. While the percentage of total Ki-67/DCX
double positive cells was decreased in SPG11 neurons, there
was no significant difference in the EdU-positive subpopulation
of the proliferating neuroblasts (EdU/Ki-67/DCX-positive cells;
Fig. 4A and B).
We next asked whether the observed phenotype can be
rescued by manipulation of the βGSK3 pathway. For this aim
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Figure 5. Rescue of SPG11 phenotypes in organoids. (A) Bright field images of control- and SPG11-organoids, NT or treated with CHIR or Tide, at 4, 6 and 9 days in
culture. (B–D) Quantification of organoid size at day 4, 6 and 9 for the respective groups. (E) Organoids (40d) stained for Ki-67 (red) and Sox2 (white). (F) Quantification
of 40d organoid proliferation (treated according to the paradigm in Supplementary Material, Fig. S4D; ∗P < 0.05, ∗∗P < 0.01 ∗∗∗P < 0.001, ∗∗∗∗P < 0.0001; (A–C): n ≥ 9
organoids per condition; E-F: n ≥ 3). All data: mean ± SD. Scale bars: 200 μm in (A); 20 μm in (E).
we employed compounds that specifically inhibit βGSK3, an
FDA-approved tideglusib and CHIR. We found that tideglusib
was able to increase the number of proliferating neuroblasts
in SPG11. (Fig. 4A and B). Interestingly, tideglusib or CHIR
treatment reduced the premature generation of neuroblasts
in SPG11-NPCs (Fig. 4C and D) and in neurosphere model,
respectively (Fig. 4E and F; paradigms Supplementary Material,
Fig. S4).
In summary, in addition to the rescue of SPATACSIN loss
of function by overexpression, also pharmacological inhibition
of ßGSK3 decreased neuroblast numbers and thus attenuated
premature neurogenesis in SPG11-NPCs.
When treating organoids with CHIR or tideglusib (paradigm
SupplementaryMaterial, Fig. S4D), SPG11 organoids significantly
increased in size compared to untreated controls (Fig. 5A–D).
We conclude that decreased organoid size in SPG11 is partially
rescued by ßGSK3 inhibition. CHIR had effects on both control-
and SPG11-organoid sizes. Interestingly, tideglusib specifically
increased the size of SPG11 organoids, but did not influence
organoid size of controls. Moreover, the significantly lower
amount of Ki-67+/Sox2+ cells at the apical surface of SPG11
organoids compared to controls was rescued by tideglusib
treatment (Fig. 5E and F). This indicates that tideglusib might
be a potent compound for SPG11 in 3D structures.
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Discussion
We employed iPSC-derived multidimensional neuronal cultures
of SPG11 patients to demonstrate that disruption of SPATACSIN
leads to impaired self-renewal of cortical NPCs, resulting in
premature neurogenesis due to an increase in asymmetric
versus symmetric division and consequently a progressively
reduced survival of neurons. The addition of an FDA-approved
βGSK3 modulator (tideglusib) increased organoid size in
SPG11.
Although animal models have provided insights into SPG11,
specifically early onset pathologies are inconsistent; a previ-
ously published SPG11-null mouse, generated by inserting a
gene-trap cassette in the first exon of the SPG11 gene, exclusively
showed late-onset motor impairments, together with a massive
loss of neurons in the cortex and cerebellum of old mice (39). In
contrast, the disruption of SPG11 by introduction of a stop codon
in exon 32, mimicking the most frequent mutation observed in
SPG11 patients, resulted in early cognitive deficits, together with
abnormal callosal projections and neuronal death in the cortex
ofmutantmice (2). This considerable variability reflects the need
for alternative strategies to decipher the function of spatacsin in
human models.
The invention of generating iPSCs opened the unique
possibility of modeling disease phenotypes in a human cellular
system (38). IPSC-derived 3D neuronal models, so-called
cerebral organoids, mimic fetal development and hold great
promise of providing the spatial and temporal solution for
elucidating disease mechanisms (5,18). Our findings parallel
cellular neurodevelopmental phenotypes recently described in
human cerebral organoids of severe lissencephalies such as the
Miller–Dieker syndrome (1) or other microcephalies (18).
Changes at the NPC stage may represent the cellular phenotype
of cortical atrophy observed in SPG11 patients. Traditionally
considered as a neurodegenerative disease with juvenile onset,
cortical MRIs of SPG11 patients evidenced early reductions
of grey matter volumes (37). These imaging studies were
complemented by the post-mortem finding of severe neuronal
loss in the frontal cortex of SPG11 patients (10). Specifically, TCC
and childhood onset atrophy of the cortex, combined with early-
onset cognitive impairment might be characteristic of early
childhood onset in SPG11 patients. Our finding that dysfunction
of SPG11 interferes with the development of iPSC-derived brain
organoids is in line with early cortical atrophy diagnosed in the
patients included in this study (15). Our data thus support the
hypothesis of an additional neurodevelopmental phenotype in
SPG11-HSP.
Our results in SPG11 iPSC-derived neural models suggest a
reduced rate of symmetric division of NPCs, a higher proportion
of proliferative neuroblasts and defects in the germinal zone
of organoids, which ultimately result in premature neurogen-
esis (Fig. 5G). More specifically, we observe defects at two dis-
tinct stages. First of all, SPG11-NPCs present with longer cell
cycle, which is complemented by increased asymmetric division
rate, resulting in increased number of neuroblasts, or premature
neurogenesis. For instance, rodent models revealed interplay
between the duration of the cell cycle and the initiation and the
total period of neurogenesis (4). A prolonged duration of mitosis
was previously connected to premature neuronal differentiation
of radial glia cells and an increase in apoptotic cells in a murine
model of mago homolog, exon junction complex core compo-
nent Magoh (33). Likewise, in humans, disease-causing muta-
tions have helped to identifymolecularmechanisms of cell cycle
and neurogenesis regulation. For example, the protocadherin 19
gene, mutated in intellectual disability, modulates neurogenesis
via excessively prolonged mitosis of progenitors (9). Second, at
neuroblast stage, there are less proliferating cells, possibly due
to premature differentiation. Overall, the combination of these
defects culminated in defective SPG11 neurons (Supplementary
Material, Fig. S6).
SPATACSIN was previously linked to a significant decrease
of axon-related genes and neurite complexity (32). Activated
GSK3 is implicated in neurogenesis, promoting the degradation
of ßCat and the activation of an array of transcription factors
like CREB, but also in glutamate-induced neuronal death
(8). Therefore, our results point out that the dysfunction
of SPATACSIN impairs the delicate balance of the GSK3
signaling system. The activation of GSK3, in turn, significantly
contributes to changes in NPC proliferation, neurogenesis
and neuronal maturation (11). Our previous observations in
SPG11-NPCs indicated impaired ßCat signaling in SPG11-NPC
that could be rescued by administration of specific βGSK3
inhibitors (25). We took advantage of this knowledge in
order to assess whether the same observations are present
also in the neurosphere and cerebral organoids models.
Along this line, two different GSK3 inhibitors (CHIR and
tideglusib) reversed neurodevelopmental defects in SPG11
cortical cultures, and organoids. Tideglusib, an FDA-approved
drug, improved cognitive function in mild Alzheimer’s Disease
(19) and is currently in phase II clinical studies for ado-
lescents with autism spectrum disorder and myotonic
dystrophy (clinicaltrials.gov). Tideglusib therefore appeals as
a promising compound based on its specificity in blocking
ßGSK3, which is the isoform distinctively implicated in
proliferation/neurogenesis tasks, and thereby rescuing SPG11
neurodevelopmental phenotypes. Furthermore, since the
blockade of GSK3 also activates lysosomal/autophagy pathways
(30), tideglusib might also attenuate aberrant accumula-
tion of membranous bodies associated with dysfunction of
SPG11 (35).
Our previous study indicated the beneficial effect of
βGSK3 inhibition on NPCs. Here, for the first time we link
SPG11/SPATACSIN in their roles for the Wnt/ßCat pathway
in a 3D brain organoid system. By confirming the potency
of tideglusib in a complex, human brain organoid system we
emphasize the clinical relevance of the compound.
In addition, our findings are the first report to decipher
impaired cortical neurogenesis in SPG11-HSP.We provide a rigor-
ous spatial and temporal analysis of the related pathology in 2D
and 3D systems. Alterations of the natural ratio of cell divisions
and proliferation rate are tightly linked to the observed mor-
phological changes of brain organoids. These observations are
crucial for the understanding of disease etiology and contribute
a novel aspect for clinical intervention.
Experimental procedures
SPG11 patients and controls
Three patients (UKERi6O6-R1, UKERi4AA-R1 and UKERiK22-R1,
described as SPG11-1, SPG11-2 and SPG11-3) and two controls
(UKERi1JF-R1 and UKERi1E4-R1) were included. Patients were
described in detail previously (15). The underlying Institutional
Review Board approval (Nr. 4120: Generierung von humanen
neuronalen Modellen bei neurodegenerativen Erkrankungen) and
informed consent were obtained at the movement disorder
clinic at the Department of Molecular Neurology, Universität-
sklinikum Erlangen (Erlangen, Germany).
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IPSC-derived neuronal model
IPSCs were reprogrammed from fibroblasts using Yamanaka’s
retroviral transduction (two iPSC lines per individual). The lines
were maintained and controlled for pluripotency as previously
described (14). From every individual, two independent NPC lines
and respective neurons were generated using an embryoid body
(EB)/rosette protocol (14) and further differentiated into neurons.
Multidimensional cultures
Cerebral organoids were generated from iPSC as previously
described (18). For control lines, EBs were generated from 9000
cells each. For patient lines, EBs were generated from 9000 and
18 000 cells with no visible difference in size or development.
Two control- and two SPG11-iPSC lines (SPG11-1 and SPG11-
2) were analyzed. Controls were grouped. Cerebral organoids
were cultured for 40 to 61 days (6 and 9 weeks) at 37◦C under
5% CO2 and atmospheric oxygen. For the rescue experiment,
control- and SPG11 organoids were treated with 1 μM of the
GSK3 blockers CHIR99021 and tideglusib and kept in culture for
40 to 60 days (6 and 9 weeks). Compounds were replaced every
2–3 days (Supplementary Material, Fig. S4D).
For the neurosphere assay (3), NPCs were kept in suspension
in 96 well ultra-low attachment plates (Corning, Amsterdam, the
Netherlands) for 72 h at a density of 5 × 104 cells/cm2 under
proliferative conditions. For the analysis of NPC migration, neu-
rospheres grew attached to polyornithine/laminin (Invitrogen,
Carlsbad, California, United States) coated coverslips for 48 h
(Fig. 2A). Spheres generated from six SPG11-NPC lines (SPG11-1,
SPG11-2 and SPG11-3) were compared to controls.
Time-lapse video microscopy
Control- and SPG11-NPCs were infected with a pEF1-GFP
lentivirus. Time-lapse assays were performed for 6 days under
mitogenic conditions. Time-lapses and single-cell tracking (29)
of SPG11- and control-NPCs were performed with a cell observer
(Zeiss Jena, Germany) at 37◦C and 5% CO2. Phase contrast
and fluorescent images were acquired every 8 and 160 min
respectively using a 20× phase contrast microscopy objective
(Zeiss), an AxioCam HRm camera and Zeiss AxioVision 4.7
software (Zeiss). Time-lapses were assembled using ImageJ
whereas single-cell tracking was carried out using a self-written
computer program (TTT). Per every assessedNPC line, at least 40–
50 videos were analyzed and 50 single cells tracked. Time-lapse
analyses were evaluated from two control- and three SPG11-
NPC lines (SPG11-1, SPG11-2 and SPG11-3). Control NPC lines
were grouped.
Statistical analysis
Immunofluorescence analyses, neurite measurement, protein
expression and phosphorylation were statistically analyzed
using Prism (GraphPad, San Diego, California, United States).
Unless indicated otherwise, all data are shown as mean ± SD.
Statistical analysis was carried out employing the Student’s t-
test for unpaired variables (two-tailed) and one-way analysis
of variance followed by Bonferroni multiple comparison tests
when three or more groups were compared. P-values < 0.05
were considered significant.
Detailed information on the transfection of human cells and
details for immunofluorescence, protein sample preparation
and western blot assays are listed in the supplemental methods.
Supplementary Material
Supplementary Material is available at HMG online.
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